A Phase 2a, Randomized, Placebo-controlled, Single Center Trial to Evaluate the Impact of Intravenous Bendavia (MTP-131) on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)

Trial Profile

A Phase 2a, Randomized, Placebo-controlled, Single Center Trial to Evaluate the Impact of Intravenous Bendavia (MTP-131) on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Reperfusion injury
  • Focus Pharmacodynamics
  • Acronyms EVOLVE
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Nov 2016 Results published in a Stealth BioTherapeutics media release.
    • 18 Nov 2016 Results presented at the American Society of Nephrology (ASN) Kidney Week 2016, according to a Stealth BioTherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top